How Japan Speeds Up Antimicrobial Approvals Using Global Data

Summary

When a pharmaceutical company wants to sell a new medicine in a different country, regulators usually demand local clinical trials to prove it works safely for their specific population. However, a new analysis shows that Japan has been taking a more global approach to approving antimicrobial medicines like antibiotics and antivirals. Researchers found that foreign clinical trial data played a key role in evaluating the effectiveness of more than 60 percent of approved antimicrobial drugs in the country.

In fact, Japanese regulators approved 40 of these medicines without requiring extra domestic bridging studies, which are smaller local trials meant to confirm foreign results. Instead of forcing companies to run redundant tests, regulators looked closely at pharmacokinetic data, which measures how the human body absorbs and processes a drug. They combined this with pharmacodynamic data, which looks at how effectively the drug fights a specific infection, along with outside factors like the local healthcare environment.

While this streamlined process is highly successful, it does not mean regulators ignore local biological differences. In one notable case, variations in how Japanese patients processed a medication required regulators to approve a completely different dosage than what was used overseas. The researchers also caution that this retrospective study only looked at antimicrobials within the unique regulatory framework of Japan, so this approach might not necessarily apply to other types of medical treatments or different global regions.

The story in numbers.

Approved antimicrobial drugs in Japan evaluated using foreign clinical data

60% (45/70)

Approvals utilizing extrapolated efficacy from outside Japan without bridging studies

40

Approval requiring a different dosage in Japan due to pharmacokinetic differences

1